A Phase 1/2 interventional study of Placebo and AMG 531 in Idiopathic Thrombocytopenic Purpura, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) and Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), sponsored by Amgen. Completed. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2014-07-25.
Sponsored by Amgen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 22nd largest by enrollment, is the only one that started in 2007, is one of 3 in phase 1/2, and was the 9th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–100
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14+
Wuhan Union Hospital, China · Sites in China
Ages 18–75
Nahda University · Sites in Egypt
Ages 18–65
By country, each count listing its studies:
romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2002; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 62 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 29 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen: 1 open now, 1 under way, 1 of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2007, is one of 2 in phase 1/2, and was the 9th registered.
Amgen’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2002.
2 of the studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206823The First Affiliated Hospital of Soochow UniversityEfficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia | 2027-02-28 |
| NCT07612319The First Affiliated Hospital of Soochow UniversityRomiplostim for Oral TPO-RA Resistant ITP | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 18 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of romiplostim (AMG 531) in the treatment of thrombocytopenia in pediatric subjects with chronic ITP. We will also evaluate the efficacy of romiplostim (AMG 531) and characterize the pharmacokinetics of romiplostim (AMG 531). It is anticipated that romiplostim (AMG 531), when given at an effective dose and schedule, will be well tolerated treatment for thrombocytopenia among pediatric subjects with chronic ITP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 thrombocytopenic (as defined per protocol) subjects
Drug: Placebo
15 thrombocytopenic (as defined per protocol) subjects
Drug: AMG 531
Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
Also known as: romiplostim
Adverse Events
Occurrence of one or more adverse events in the participant during the 12-week treatment period
Time frame: 12 weeks
Weeks With Platelet Count ≥ 50 x 10^9/L
The number of weeks with platelet count ≥ 50 x 10\^9/L during the 12 week treatment period.
Time frame: 12-week treatment period
Bleeding Events (Grade 2 or Higher)
Total number of bleeding events (Grade 2 or higher, i.e., mild to life-threatening, as defined in the protocol) for each participant during Weeks 2-13 (end-of-study visit for non-responders)
Time frame: 12-week treatment period (Weeks 2 - 13)
Platelet Count ≥ 50 x 10^9/L for Two Consecutive Weeks
Participant incidence of achieving a platelet count ≥50 x 10\^9/L for two consecutive weeks during the 12 week treatment period.
Time frame: 12-week treatment period
Increase in Platelet Count ≥ 20 x 10^9/L Above Baseline for Two Consecutive Weeks
Participant incidence of achieving an increase in platelet count ≥20 x 10\^9/L above baseline for two consecutive weeks during the 12 week treatment period.
Time frame: 12-week treatment period
Requirement for Rescue Therapy (as Defined Per Protocol)
Participant required rescue therapy (as defined per protocol) during the 12 week treatment period.
Time frame: 12-week treatment period
Participants were enrolled from 19 Jul 2007 through 11 November 2008
| Milestone | Romiplostim | Placebo |
|---|---|---|
| Started | 17 | 5 |
| Completed | 17 | 5 |
| Not completed | 0 | 0 |
The number of weeks with platelet count ≥ 50 x 10\^9/L during the 12 week treatment period.
| Weeks | Romiplostim | Placebo |
|---|---|---|
| Weeks With Platelet Count ≥ 50 x 10^9/L | 5.65 ± 3.00 | 0.00 ± 0.00 |
Total number of bleeding events (Grade 2 or higher, i.e., mild to life-threatening, as defined in the protocol) for each participant during Weeks 2-13 (end-of-study visit for non-responders)
| Events per participant | Romiplostim | Placebo |
|---|---|---|
| Bleeding Events (Grade 2 or Higher) | 0.41 ± 1.00 | 0.00 ± 0.00 |
Participant incidence of achieving a platelet count ≥50 x 10\^9/L for two consecutive weeks during the 12 week treatment period.
| Participants | Romiplostim | Placebo |
|---|---|---|
| Platelet Count ≥ 50 x 10^9/L for Two Consecutive Weeks | 15 | 0 |
Participant incidence of achieving an increase in platelet count ≥20 x 10\^9/L above baseline for two consecutive weeks during the 12 week treatment period.
| Participants | Romiplostim | Placebo |
|---|---|---|
| Increase in Platelet Count ≥ 20 x 10^9/L Above Baseline for Two Consecutive Weeks | 15 | 0 |
Participant required rescue therapy (as defined per protocol) during the 12 week treatment period.
| Participants | Romiplostim | Placebo |
|---|---|---|
| Requirement for Rescue Therapy (as Defined Per Protocol) | 2 | 2 |
Occurrence of one or more adverse events in the participant during the 12-week treatment period
| Participants | Romiplostim | Placebo |
|---|---|---|
| Adverse Events | 16 | 5 |
Collected over 12 week treatment period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/5 (0%) | 5/5 (100%) |
| Romiplostim | — | 1/17 (5.9%) | 16/17 (94.1%) |
| Event | Placebo | Romiplostim |
|---|---|---|
| InfluenzaInfections and infestations | 0/5 | 1/17 |
| SepsisInfections and infestations | 0/5 | 1/17 |
| Event | Placebo | Romiplostim |
|---|---|---|
| VomitingGastrointestinal disorders | 2/5 | 2/17 |
| HeadacheNervous system disorders | 2/5 | 6/17 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/5 | 2/17 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/5 | 0/17 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/5 | 6/17 |
| PyrexiaGeneral disorders | 0/5 | 4/17 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/5 | 4/17 |
| Abdominal painGastrointestinal disorders | 1/5 | 1/17 |
| Injection site haematomaGeneral disorders | 1/5 | 0/17 |
| MalaiseGeneral disorders | 1/5 | 0/17 |
| Age, Continuous(Years) | Romiplostim | Placebo | Total |
|---|---|---|---|
| Mean | 9.4 ± 5.4 | 9.8 ± 4.6 | 9.5 ± 5.1 |
| Sex: Female, Male(Participants) | Romiplostim | Placebo | Total |
|---|---|---|---|
| Female | 4 | 2 | 6 |
| Male | 13 | 3 | 16 |
| Race/Ethnicity, Customized(Participants) | Romiplostim | Placebo | Total |
|---|---|---|---|
| White or Caucasian | 9 | 4 | 13 |
| Black or African American | 5 | 0 | 5 |
| Hispanic or Latino | 3 | 0 | 3 |
| Other | 0 | 1 | 1 |
No study locations are listed for this record.
The record gives a start of Jul 2007, a primary completion of Mar 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim
Purpura, Thrombocytopenic, Idiopathic →